Skip to content
Study details
Enrolling now

Bintrafusp Alfa and PDS01ADC Trial

National Cancer Institute (NCI)
NCT IDNCT04235777ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

100

Study length

about 7.4 years

Ages

18–120

Locations

1 site in MD

What this study is about

Researchers are testing a treatment with M7824, PDS01ADC, and SBRT to see if it can help fight cancer that has spread. Participants will receive these treatments through injections and infusions over several months while also providing samples for research purposes. The trial will last approximately 2 years.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive Stereotactic body radiation therapy (SBRT)
  • 2.Take M7824
  • 3.Take PDS01ADC

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Standard assignment

Assignment is predetermined by the study protocol.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: safety and tolerability of PDS01ADC and M7824 alone or in combination with SBRT

Secondary: Objective response rate (ORR), Overall Survival (OS), Progression free survival (PFS)

Body systems

Oncology